Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Health, Fitness & Food

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Products You May Like

Articles You May Like

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
Autumn Whipped Ricotta Dip
How we’re thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
Sweet Potato Casserole with Praline Topping

Leave a Reply

Your email address will not be published. Required fields are marked *